Advanced Genomic Analysis Technology to Support Genomics and Biomedical Genetics
Research
CARLSBAD, Calif.--(Business Wire)--
The University of Cambridge and Life Technologies Corporation (NASDAQ:LIFE),
announced today the formation of a collaboration to advance translational
research studies in key disease areas such as cancer, diabetes and neurological
disorders. Through this collaboration, next generation sequencing technology
will be made available to the European research and clinical communities through
the Eastern Sequence and Informatics Hub at Addenbrooke`s Hospital in Cambridge.
The Cambridge based hub was established with funding from the Medical Research
Council and from the University`s Clinical School and NIHR Biomedical Research
Centre to accelerate the use of genetic information to help identify new
therapies, diagnostics and preventive strategies. Genomics and biomedical
scientists will use three SOLiD 3 Plus Systems, next-generation DNA sequencing
platforms from Life Technologies, to advance targeted medical resequencing and
whole transcriptome analysis research studies.
"We are at an exciting point in history where technologies such as the SOLiD
System, provide the throughput and accuracy required for comprehensive
characterization of disease systems," said Professor John Todd of the University
of Cambridge and principal investigator at the Eastern Sequence and Informatics
Hub, Addenbrooke`s Hospital. "The translation of this information into
clinically relevant knowledge will have a direct impact on the treatment of
human disease through the development of better diagnostic, prognostic and
therapeutic agents."
"The collaboration with the University of Cambridge`s Eastern Sequence and
Informatics Hub, underlines our commitment to help deliver the potential of
translational research and accelerate the realization of personalized medicine,"
said Shaf Yousaf, President, Genomic Analysis at Life Technologies. "The SOLiD
System offers an optimized and integrated next-generation sequencing solution to
provide researchers with the required throughput, accuracy, speed and
flexibility for a wide range of genetic investigations."
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools
company dedicated to improving the human condition. Our systems, consumables and
services enable researchers to accelerate scientific exploration, driving to
discoveries and developments that make life even better. Life Technologies
customers do their work across the biological spectrum, working to advance
personalized medicine, regenerative science, molecular diagnostics, agricultural
and environmental research, and 21st century forensics. Life Technologies had
sales of more than $3 billion in 2008, employs approximately 9,500 people, has a
presence in more than 100 countries, and possesses a rapidly growing
intellectual property estate of approximately 3,600 patents and exclusive
licenses. Life Technologies was created by the combination of Invitrogen
Corporation and Applied Biosystems Inc. For more information on how we are
making a difference please visit our website: www.lifetechnologies.com. Follow
Life Technologies on Twitter @LIFECorporation and on Facebook.
800 Years Transforming Tomorrow
The University of Cambridge was founded in 1209 and celebrates its 800th
anniversary this year. Its mission is to contribute to society through the
pursuit of education, learning and research at the highest international levels
of excellence. It is made up of 31 colleges and more than 100 departments that
cater for some 12,000 undergraduate and 6,000 postgraduate students. In a
beautiful setting by the River Cam, Cambridge is famed for the architecture of
its historic colleges but also for its wealth of modern research and teaching
facilities. The University`s reputation for outstanding academic achievement is
known worldwide and reflects the intellectual achievement of its students, as
well as the world-class original research carried out by the staff of the
University and the Colleges. Some of the world`s most significant scientific
breakthroughs have occurred at the University, including the splitting of the
atom, invention of the jet engine and the discoveries of stem cells, plate
tectonics, pulsars and the structure of DNA. From Isaac Newton to Stephen
Hawking, the University has nurtured some of history`s greatest minds and has
produced more Nobel Prize winners than any other UK institution with more than
80 laureates. Cambridge's great libraries and collections housed in eight
world-class museums and in the colleges are scholarly resources of outstanding
international significance.
Cambridge attracts the brightest and best students, researchers and academics
from across the world, with a student population drawn from 135 different
countries. www.cam.ac.uk
Life Technologies` Safe Harbor Statement
This press release includes forward-looking statements about our anticipated
results that involve risks and uncertainties. Some of the information contained
in this press release, including, but not limited to, statements as to industry
trends and Life Technologies` plans, objectives, expectations and strategy for
its business, contains forward-looking statements that are subject to risks and
uncertainties that could cause actual results or events to differ materially
from those expressed or implied by such forward-looking statements. Any
statements that are not statements of historical fact are forward-looking
statements. When used, the words "believe," "plan," "intend," "anticipate,"
"target," "estimate," "expect" and the like, and/or future tense or conditional
constructions ("will," "may," "could," "should," etc.), or similar expressions,
identify certain of these forward-looking statements. Important factors which
could cause actual results to differ materially from those in the
forward-looking statements are detailed in filings made by Life Technologies
with the Securities and Exchange Commission. Life Technologies undertakes no
obligation to update or revise any such forward-looking statements to reflect
subsequent events or circumstances.
For Research Use Only. Not for use in diagnostic procedures.
Life Technologies
Patty Zamora, 760-476-7818
patty.zamora@lifetech.com
or
Editorial contact for further information or follow-up
kdm communications limited, Bedford, UK
Sarah Khan, +44 (0) 1234 210555
Fax: +44 (0) 1234 342397
ideas@kdm-communications.com
or
University of Cambridge
Becky Allen, +44 (0)1223 765542
Fax: +44 (0)1223 330262
Office of Communications
Copyright Business Wire 2009
